Tag: annual report

Stellantis Publishes Preliminary and Unaudited Key Figures for First Half 2025

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

EURneffy (neffy^® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

State Authorizations Mean Even More Adult Smokers Will Be Able to Purchase VLN^®, Partner VLN^®, Smoker Friendly and Pinnacle Products

SALT LAKE CITY, July 17, 2025 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, will hold a conference call on Thursday, July 31, 2025, at 5:00 pm ET to discuss its financial results for the second quarter ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Luxembourg – 17 July 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a large¹ contract by Equinor relating to the Fram Sør development project, offshore Norway.